RT Journal Article
T1 COVID-19  vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations.
A1 Jutel, Marek
A1 Torres, Maria J
A1 Palomares, Oscar
A1 Akdis, Cezmi A
A1 Eiwegger, Thomas
A1 Untersmayr, Eva
A1 Barber, Domingo
A1 Zemelka-Wiacek, Magdalena
A1 Kosowska, Anna
A1 Palmer, Elizabeth
A1 Vieths, Stefan
A1 Mahler, Vera
A1 Canonica, Walter G
A1 Nadeau, Kari
A1 Shamji, Mohamed H
A1 Agache, Ioana
K1 Covid-19
K1 Allergen
K1 Allergy
K1 Biologicals
K1 Immunotherapy
K1 mRNA vaccines
AB Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)-5 and IL-4/IL-13 or non-type 2 response: anti-cytokine antibodies and B-cell depletion via anti-CD20. Coronavirus disease 2019 (COVID-19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals.
PB John Wiley & Sons
YR 2022
FD 2022-08-06
LK http://hdl.handle.net/10668/19898
UL http://hdl.handle.net/10668/19898
LA en
NO Jutel M, Torres MJ, Palomares O, Akdis CA, Eiwegger T, Untersmayr E, et al.  COVID-19  vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations. Allergy. 2022 Aug;77(8):2313-2336
DS RISalud
RD Apr 18, 2025